About

Professor Vincent Lawton is Chairman of Addex's Board of Directors, chairs the Audit Committee and is a member of the Compensation Committee. He was Vice President Merck Europe and Managing Director of MSD UK until he stepped down in 2006, after 26 years' service internationally for Merck & Co. He was appointed CBE for services to the pharmaceutical industry and, as President of the ABPI, helped establish the UK as a leading centre of clinical research. He served on the board of the UK regulatory authority (MHRA) from 2008 to 2015, was Senior Strategy Adviser for Imperial College Department of Medicine and is a board member of Neurosterix. He studied Psychology at the University of London, where he holds an undergraduate degree and a PhD.

Roles

Addex Therapeutics Ltd.
Chairman of the Board of Directors (Independent) · Current role
Present
Merck & Co / MSD UK
VP Merck Europe and Managing Director, MSD UK · 26 years' international service
- 2006
MHRA (UK regulatory authority)
Board member
2008 - 2015
ABPI
President · UK pharmaceutical industry association

External Roles

Neurosterix
Board member
present
Imperial College, Department of Medicine
Senior Strategy Adviser
present

Director Compensation

FY 2025
Fixed compensation
CHF 29,015
ComponentFixed annual Board compensation, FY2025 (CHF); Chairman of the Board
Variable cash (attendance)
CHF 29,015
ComponentVariable cash based on Board-meeting attendance, FY2025
Total
CHF 58,030
BasisNo equity incentive units were granted to Board members in 2025.

Also at Addex Therapeutics Ltd.

Related

See how VectorShift works for your firm

Request Demo